Seagen and Zai Lab ink partnership on Tivdak expansion into China and surrounding areas; NC biotech snaps up seed funding
Zai Lab has signed on to commercialize Seagen and Genmab’s Tivdak — an ADC for recurrent or metastatic cervical cancer in patients in which chemotherapy isn’t working — in mainland China, Hong Kong, Macau and Taiwan.
Seagen will get $30 million upfront, along with downstream milestone payments and tiered royalties. But the company will be splitting all earnings from the Zai Lab agreement 50:50 with Genmab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.